Impact of Pitavastatin in Hypercholesterolemic Patients With Metabolic Syndrome
Multicenter Study for Anti-oxidative and Anti-inflammatory Effects of Pitavastatin in Hypercholesterolemic Patients With Metabolic Syndrome
  • Phase

    Phase 4
  • Study Type

  • Status

    Completed No Results Posted
  • Study Participants

The purpose of this study is to evaluate anti-oxidative and anti-inflammatory effects of pitavastatin in hypercholesterolemic patients with the metabolic syndrome.
The metabolic syndrome is defined as a cluster of cardiovascular risk factors including visceral obesity, dyslipidemia, elevated blood pressure and impaired glucose tolerance. Recently, it has been described that oxidative stress and inflammatory reaction, which are important in progression of atherosclerosis, increases in individuals with the metabolic syndrome. Statins might have beneficial effects such as anti-oxidative and anti-inflammatory actions that are independent from their cholesterol-lowering effects. Pitavastatin, a chemically synthesized statin, has potent LDL-cholesterol lowering and also anti-oxidative and anti-inflammatory effects in animal studies. However, the effects of pitavastatin on oxidative stress and inflammatory action in patients with the metabolic syndrome have not been reported.
Study Started
Apr 30
Primary Completion
Sep 30
Study Completion
Sep 30
Last Update
Jul 13

Drug pitavastatin

Pitavastatin (2mg/day) was administered for 12 weeks

  • Other names: livalo


Inclusion Criteria:

Hypercholesterolemic patients

Exclusion Criteria:

Patients receiving lipid-lowering agents
Familial hypercholesterolemia
Renal disease
Diseases of liver, gallbladder and bile ducts
Pregnant women
No Results Posted